Movano Health reports Q3 net loss of $8.6M; progress on FDA submission and beta programs

Corvex, Inc.

2022-Q3 EPS reported -$0.68

Net loss of $8.6M ($0.26 diluted EPS) vs $5.2M ($0.16) in Q3 2021; no revenue.
Cash and short-term investments $16.8M at Sept 30, down from $33.6M at Dec 31, 2021.
Raised $1.9M via ATM facility in Q3; 33.5M shares outstanding.
Plans to file for FDA clearance for heart rate and SpO2 in early 2023 after pivotal hypoxia study.
Beta programs underway with Novant Health, Stanford, and two other partners; product launch expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvex, Inc. reported three months ending September 30, 2022 results: net income $8.6 million, EPS $(0.26) per basic and diluted share.

Period: three months ending September 30, 2022
Net income: $8.6 million
EPS: $(0.26) per basic and diluted share
Result: reported results

Exact text from the filing

Movano Health reported a net loss attributable to common stockholders of $8.6 million, or a loss of $(0.26) per basic and diluted share, in the third quarter of 2022

View on SEC.gov

Browse all earnings releases →

Corvex, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-072330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.